Indianapolis – October 15, 2026 -- More than one in four ulcerative colitis (UC) patients (27.7%) treated with Eli Lilly and Company's Omvoh (mirikizumab-mrkz) achieved comprehensive disease control at one year, compared with 14% on placebo, according to a post hoc analysis of the LUCENT-2 trial.
In the VIVID-1 Crohn's disease trial, 20.4% of Omvoh-treated patients reached corticosteroid-free deep remission, versus 2% on placebo. Lilly will present both analyses at United European Gastroenterology (UEG) Week 2026.
Omvoh delivers 23.4% comprehensive control in UC patients with prior biologic failure
Comprehensive disease control is a novel composite outcome informed by an international expert consensus. It combines clinical remission, no corticosteroid use for at least 12 weeks before Week 52, histologic remission and fecal calprotectin of 250 μg/g or lower. Lilly states Omvoh is the first IL-23p19 inhibitor evaluated against this endpoint in UC.
The analysis covered patients who responded to Omvoh at Week 12 of the LUCENT-1 induction study and were re-randomized in LUCENT-2 to continue treatment or switch to placebo. Of these, 35.3% had previously experienced biologic treatment failure. In that subgroup, 23.4% of Omvoh-treated patients achieved comprehensive disease control, versus 9.4% on placebo.
Quality-of-life remission reaches 91.1% among UC patients with comprehensive control
Among Omvoh-treated UC patients who achieved comprehensive disease control, 91.1% also reached remission on the Inflammatory Bowel Disease Questionnaire (IBDQ), against 65.2% of those who did not. These patients were also more likely to report no to minimal bowel urgency and greater improvements in work productivity.
VIVID-1 shows 15.7% deep remission in Crohn's patients with prior biologic failure, versus none on placebo
Corticosteroid-free deep remission combines clinical remission (measured by the Crohn's Disease Activity Index), endoscopic remission and no corticosteroid use for at least 12 weeks before Week 52. Nearly half of the VIVID-1 population (48.6%) had experienced biologic failure. Among those patients, 15.7% on Omvoh reached the endpoint; no placebo patient did.
IBDQ remission was achieved by 88.1% of Omvoh-treated Crohn's patients who hit deep remission, versus 51% of those who did not.
Anabela Cardoso, senior vice president of Lilly Immunology Medical Affairs, said the data show that a higher bar for disease control is achievable. Stefan Schreiber, M.D., of University Hospital Schleswig-Holstein and Christian-Albrecht University of Kiel, described the endpoints as a shift in how treatment success is defined.
Safety profile unchanged; Omvoh approved in 47 countries
Safety findings from the Phase 3 programs were reported previously. Common adverse reactions in LUCENT-1 and -2 included upper respiratory tract infections, injection site reactions, arthralgia, rash, headache and herpes viral infection. In VIVID-1, they included upper respiratory tract infections, injection site reactions, headache, arthralgia and elevated liver tests.
Omvoh is approved for moderately to severely active UC and Crohn's disease in adults in 47 countries. A single-injection maintenance regimen for UC is approved in several markets, including the U.S., EU, Canada and Japan.
Lilly runs combination trials pairing mirikizumab with eltrekibart, zotemtegrast, an FXR agonist and incretins
In UC, Lilly is testing mirikizumab with eltrekibart (NCT06598943), a monoclonal antibody targeting neutrophil-driven inflammation, and with zotemtegrast (NCT07186101), an oral α4β7 integrin inhibitor. In Crohn's disease, it is studying mirikizumab with an FXR agonist (NCT07483099).
The COMMIT-UC (NCT06937086) and COMMIT-CD (NCT06937099) trials are evaluating mirikizumab alongside an incretin-based therapy in adults with UC or Crohn's disease and obesity or overweight with at least one weight-related comorbidity. Pediatric studies are ongoing, including a long-term extension in UC and Crohn's disease (NCT04844606) and a Phase 3 trial in pediatric Crohn's disease (NCT05509777).